Pharmacologic treatment of anorexia nervosa: Where do we go from here?
Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized find...
Gespeichert in:
Veröffentlicht in: | The International journal of eating disorders 2005, Vol.37 (S1), p.S60-S63 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S63 |
---|---|
container_issue | S1 |
container_start_page | S60 |
container_title | The International journal of eating disorders |
container_volume | 37 |
creator | Attia, Evelyn Schroeder, Laura |
description | Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc. |
doi_str_mv | 10.1002/eat.20133 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67809949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67809949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQhi0EglI48ALIJyQOab1l44Iq1AWprCoqN8txJhBIYrBTKG9PSgqcEKeRRt98M_MjdEBJjxLC-qDqHiOU8w3UoSSOPEqi-03UISwMPC7CaAftOvdECAk48bfRDvUjn3HGOmh0_ahsqbQpzEOucW0bVwlVjU2GVWUsLHOFK7BvxqkTPH8ECzg1-B3wg8GZNSVetU730FamCgf769pFd6Ph7GziTa_G52eDqadFs9BLUwphxkPNfEgSpTnTCUsob85KidZCs4QnzcGaKl-okCaCZjFnGRcCBMlS3kVHrffFmtcFuFqWudNQFKoCs3AyCCMSxyL-F2QkDDhnK_C4BbU1zlnI5IvNS2U_JCVyla5sEpFf6Tbs4Vq6SEpIf8l1nA3Qb4H3vICPv01yOJh9K712Inc1LH8mlH1ufuGhL-eXYxnc31yIyexWzvgngXuSRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20763329</pqid></control><display><type>article</type><title>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Attia, Evelyn ; Schroeder, Laura</creator><creatorcontrib>Attia, Evelyn ; Schroeder, Laura</creatorcontrib><description>Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.</description><identifier>ISSN: 0276-3478</identifier><identifier>EISSN: 1098-108X</identifier><identifier>DOI: 10.1002/eat.20133</identifier><identifier>PMID: 15852322</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>anorexia nervosa ; Anorexia Nervosa - drug therapy ; Antidepressive Agents - therapeutic use ; Antipsychotic Agents - therapeutic use ; eating disorders ; Gastrointestinal Agents - therapeutic use ; Humans ; medication ; Narcotic Antagonists - therapeutic use ; pharmacology ; review</subject><ispartof>The International journal of eating disorders, 2005, Vol.37 (S1), p.S60-S63</ispartof><rights>Copyright © 2005 Wiley Periodicals, Inc.</rights><rights>2005 by Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</citedby><cites>FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feat.20133$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feat.20133$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,4010,27902,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15852322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Attia, Evelyn</creatorcontrib><creatorcontrib>Schroeder, Laura</creatorcontrib><title>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</title><title>The International journal of eating disorders</title><addtitle>Int. J. Eat. Disord</addtitle><description>Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.</description><subject>anorexia nervosa</subject><subject>Anorexia Nervosa - drug therapy</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>eating disorders</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>medication</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>pharmacology</subject><subject>review</subject><issn>0276-3478</issn><issn>1098-108X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQhi0EglI48ALIJyQOab1l44Iq1AWprCoqN8txJhBIYrBTKG9PSgqcEKeRRt98M_MjdEBJjxLC-qDqHiOU8w3UoSSOPEqi-03UISwMPC7CaAftOvdECAk48bfRDvUjn3HGOmh0_ahsqbQpzEOucW0bVwlVjU2GVWUsLHOFK7BvxqkTPH8ECzg1-B3wg8GZNSVetU730FamCgf769pFd6Ph7GziTa_G52eDqadFs9BLUwphxkPNfEgSpTnTCUsob85KidZCs4QnzcGaKl-okCaCZjFnGRcCBMlS3kVHrffFmtcFuFqWudNQFKoCs3AyCCMSxyL-F2QkDDhnK_C4BbU1zlnI5IvNS2U_JCVyla5sEpFf6Tbs4Vq6SEpIf8l1nA3Qb4H3vICPv01yOJh9K712Inc1LH8mlH1ufuGhL-eXYxnc31yIyexWzvgngXuSRg</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Attia, Evelyn</creator><creator>Schroeder, Laura</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</title><author>Attia, Evelyn ; Schroeder, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>anorexia nervosa</topic><topic>Anorexia Nervosa - drug therapy</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>eating disorders</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>medication</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>pharmacology</topic><topic>review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Attia, Evelyn</creatorcontrib><creatorcontrib>Schroeder, Laura</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of eating disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Attia, Evelyn</au><au>Schroeder, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</atitle><jtitle>The International journal of eating disorders</jtitle><addtitle>Int. J. Eat. Disord</addtitle><date>2005</date><risdate>2005</risdate><volume>37</volume><issue>S1</issue><spage>S60</spage><epage>S63</epage><pages>S60-S63</pages><issn>0276-3478</issn><eissn>1098-108X</eissn><abstract>Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15852322</pmid><doi>10.1002/eat.20133</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0276-3478 |
ispartof | The International journal of eating disorders, 2005, Vol.37 (S1), p.S60-S63 |
issn | 0276-3478 1098-108X |
language | eng |
recordid | cdi_proquest_miscellaneous_67809949 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | anorexia nervosa Anorexia Nervosa - drug therapy Antidepressive Agents - therapeutic use Antipsychotic Agents - therapeutic use eating disorders Gastrointestinal Agents - therapeutic use Humans medication Narcotic Antagonists - therapeutic use pharmacology review |
title | Pharmacologic treatment of anorexia nervosa: Where do we go from here? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A24%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacologic%20treatment%20of%20anorexia%20nervosa:%20Where%20do%20we%20go%20from%20here?&rft.jtitle=The%20International%20journal%20of%20eating%20disorders&rft.au=Attia,%20Evelyn&rft.date=2005&rft.volume=37&rft.issue=S1&rft.spage=S60&rft.epage=S63&rft.pages=S60-S63&rft.issn=0276-3478&rft.eissn=1098-108X&rft_id=info:doi/10.1002/eat.20133&rft_dat=%3Cproquest_cross%3E67809949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20763329&rft_id=info:pmid/15852322&rfr_iscdi=true |